Syphilis Testing Market Outlook: Increasing Disease Screening and Growth Opportunities

According to IMARC Group's latest research publication, The global syphilis testing market size reached USD 1.34 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.07 Billion by 2034, exhibiting a growth rate (CAGR) of 4.82% during 2026-2034.

How AI is Reshaping the Future of the Syphilis Testing Market

• AI-Powered Diagnostic Accuracy and Smart Device Development: AI is transforming the syphilis testing landscape by enabling smart diagnostic devices capable of detecting infection markers automatically with minimal sample volumes. Machine learning algorithms process test results with greater precision, reducing human error and improving specificity and sensitivity. AI supports real-time monitoring of testing data across populations, helping identify hotspots and inform public health interventions.
• Point-of-Care Automation and Rapid Result Delivery: AI-driven automation is transforming point-of-care testing platforms from manual to fully automated systems, delivering results in significantly shorter timeframes. In February 2025, Roche Diagnostics expanded into molecular point-of-care testing for sexually transmitted infections with its cobas LIAT CT/NG assays, delivering lab-grade results in just 20 minutes from a single vaginal swab.
• Multiplex Testing Platform Optimization: AI enables the development of multiplex testing platforms that analyze multiple infection markers simultaneously from a single sample. These platforms can detect multiple infections, including HIV, syphilis, and gonorrhea, in a single test, reducing time and cost. AI algorithms optimize marker detection thresholds within these combined panels, ensuring that co-infections are not missed while minimizing false positives, a critical requirement for population-scale screening programs targeting high-risk groups.

Explore Updated 2026 Market Trends & Analysis

Syphilis Testing Industry Overview

With more than 2.4 million syphilis, gonorrhea, and chlamydia cases reported in 2023 in the United States alone, expanding test coverage has become a critical public health priority. Syphilis cases in particular have surged alarmingly. Syphilis cases rose 80% between 2018 and 2022, and congenital cases spiked nearly 937% over the past decade. This epidemiological pressure is directly accelerating demand for more accessible, faster, and more affordable diagnostic solutions across both developed and emerging markets. WHO Member States set a target to reduce annual syphilis cases from 7.1 million to 0.71 million by 2030. However, in 2022, 8 million new syphilis infections were reported among individuals aged 15 to 49, up by over 1 million, with the greatest increases recorded in the Americas and Africa. This trajectory underscores the urgent role that expanded testing infrastructure and screening programs must play in global STI elimination strategies.

Syphilis Testing Market Trends and Drivers

The most foundational driver of market growth is the escalating global burden of syphilis infections, which is pushing governments and healthcare providers to deploy testing more aggressively. In November 2024, NOWDiagnostics announced the nationwide launch of its First To Know Syphilis Test, the first and only FDA-authorized over-the-counter rapid test for syphilis in the United States, available at major retailers and online for under USD 30, providing results within 15 minutes from a capillary blood sample.

The prenatal and maternal health segment is receiving specific policy attention. In April 2025, the William J. Clinton Foundation partnered with the Government of West Bengal, India, to launch a triple elimination initiative targeting the prevention of mother-to-child transmission of HIV, syphilis, and hepatitis B. The program aims to strengthen maternal and child healthcare by ensuring early testing, treatment, and follow-up for pregnant women.

At-home testing is emerging as one of the most transformative delivery channels in the market. The at-home syphilis testing market is valued at USD 432.4 million in 2025 and is projected to reach USD 1,245.6 million by 2035, reflecting nearly 2.88 times growth over the forecast period. Rapid test kits dominate this segment with a 46.7% share, driven by finger-prick formats that enable instant, private screening without clinic visits. Industry investment is also accelerating to meet rising demand. In January 2025, Bio-Rad Laboratories invested USD 50 million in its molecular diagnostics division to develop new syphilis testing solutions, aiming to enhance its presence in the global infectious disease testing market.

Leading Companies Operating in the Global Syphilis Testing Industry

• Abbott Laboratories
• Becton Dickinson and Company
• Bio-Rad Laboratories Inc.
• Danaher Corporation
• DRG International Inc. (BioCheck Inc.)
• F. Hoffmann-La Roche AG
• Siemens Healthineers AG (Siemens AG)
• Thermo Fisher Scientific Inc.

Syphilis Testing Market Report Segmentation

By Type:

• Primary and Secondary Syphilis
• Latent and Tertiary Syphilis

Primary and secondary syphilis represents the largest segment, as early-stage testing is most actionable for treatment and transmission prevention, making it the focus of public health screening programs worldwide.

By Location of Testing:

• Laboratory Testing
• Point-of-Care (POC) Testing

Laboratory testing accounts for the largest market share, owing to its superior diagnostic accuracy, ability to simultaneously process multiple infection markers, and preference among healthcare providers for confirmatory diagnosis in asymptomatic cases.

Regional Insights:

• North America (United States, Canada)
• Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
• Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
• Latin America (Brazil, Mexico, Others)
• Middle East and Africa

North America accounts for 41.3% of the global syphilis testing market, driven by a well-established healthcare system, extensive awareness programs, and government initiatives to control STIs. Asia Pacific is the fastest-growing regional segment. Governments in India, China, and Thailand have phased in diagnostic services through public hospitals, mobile clinics, and subsidized test kits, with India's National AIDS Control Organisation rolling out HIV and syphilis testing across thousands of primary healthcare centers.

Recent News and Developments in the Syphilis Testing Market

• July 2025: Health Canada approved MedMira's Multiplo TP/HIV rapid test for investigational use, paving the way for self-testing and non-professional testing. This initiative, supported by clinical research from REACH Nexus, aims to improve early detection and response to growing cases of HIV and syphilis.
• June 2025: Telehealth provider Call My Doctor introduced a discreet, at-home STD testing service in Dubai, offering comprehensive panels including HIV and syphilis, with DHA-certified nurses collecting samples privately from homes or hotels.
• April 2025: The William J. Clinton Foundation partnered with the Government of West Bengal, India, to launch a triple elimination initiative targeting prevention of mother-to-child transmission of HIV, syphilis, and hepatitis B, with the goal of every baby being born infection-free.
• March 2025: BioLytical Laboratories Inc. launched the INSTI HIV-1/2 Syphilis Test in Australia, expanding access to rapid dual-infection screening supported by government programs encouraging sexual health screening.
• February 2025: Roche Diagnostics expanded into molecular point-of-care testing with its cobas LIAT CT/NG assays, which received FDA clearance with a CLIA waiver, delivering lab-grade PCR results in just 20 minutes.
• January 2025: Bio-Rad Laboratories invested USD 50 million in its molecular diagnostics division to develop new syphilis testing solutions, reinforcing its position in the global infectious disease testing market.
• November 2024: NOWDiagnostics launched the First To Know Syphilis Test nationally in the United States, marking the first FDA-authorized over-the-counter at-home syphilis rapid test, available for under USD 30 with results in 15 minutes.
• October 2024: Chembio Diagnostics highlighted its DPP rapid tests, including the HIV-Syphilis combo, at the SCASM conference and the National Conference on Correctional Health Care, emphasizing point-of-care testing for faster onsite screening in acute care and correctional health settings.
• August 2024: Hologic received FDA approval for its Panther Fusion Syphilis Total assay, a fully automated laboratory platform designed to improve accuracy and efficiency of syphilis testing at scale.

Note: If you require specific details, data, or insights that are not currently included in the scope of this report, we are happy to accommodate your request. As part of our customization service, we will gather and provide the additional information you need, tailored to your specific requirements. Please let us know your exact needs, and we will ensure the report is updated accordingly to meet your expectations.